precisionmedicineonline15h
Adaptive Biotechnologies' MRD Test May Allow Some Mantle Cell Lymphoma Patients to Skip Transplant
A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...
precisionmedicineonline17h
ASH24 Gene Therapy Readouts in Sickle Cell, TDT: Editas, Vertex, Beam, Bluebird Bio
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...
precisionmedicineonline14h
Researchers Test Single-Cell Whole-Genome Sequencing to Select Therapy in Relapsed Multiple Myeloma
At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.
precisionmedicineonline18h
New Institute Launches With £55M to Fuel Precision Medicine R&D in Northern Ireland
The new Future Medicines Institute, based at Queen's University Belfast, is backed by government and industry.
precisionmedicineonline15h
Accent Therapeutics Treats First Patient in Phase I DHX9 Inhibitor Trial
The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.
precisionmedicineonline15h
Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination
Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.